These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34967450)

  • 1. Use of naldemedine is associated with reduced incidence of hyperactive delirium in cancer patients with opioid-induced constipation: A nationwide retrospective cohort study in Japan.
    Abe H; Sumitani M; Matsui H; Inoue R; Fushimi K; Uchida K; Yasunaga H
    Pharmacotherapy; 2022 Mar; 42(3):241-249. PubMed ID: 34967450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gabapentinoid Use Is Associated With Reduced Occurrence of Hyperactive Delirium in Older Cancer Patients Undergoing Chemotherapy: A Nationwide Retrospective Cohort Study in Japan.
    Abe H; Sumitani M; Matsui H; Inoue R; Konishi M; Fushimi K; Uchida K; Yasunaga H
    Anesth Analg; 2022 Aug; 135(2):362-369. PubMed ID: 35560025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with non-response to naldemedine for opioid-induced constipation in cancer patients: A subgroup analysis.
    Kanbayashi Y; Shimizu M; Ishizuka Y; Sawa S; Yabe K; Uchida M
    PLoS One; 2022; 17(12):e0278823. PubMed ID: 36490241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials.
    Hale M; Wild J; Reddy J; Yamada T; Arjona Ferreira JC
    Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):555-564. PubMed ID: 28576452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Naldemedine Administration for Opioid-Induced Constipation in Cancer Patients with Poor Performance Status.
    Fujita Y; Imai H; Hiruta E; Masuno T; Yamazaki S; Tanaka H; Kamiya T; Sandoh M; Takei S; Arai K; Nishiba H; Mogi J; Koizuka S; Saito T; Obayashi K; Kaira K; Minato K
    J Palliat Med; 2023 Apr; 26(4):548-553. PubMed ID: 36971576
    [No Abstract]   [Full Text] [Related]  

  • 6. Naldemedine is associated with earlier defecation in critically ill patients with opioid-induced constipation: A retrospective, single-center cohort study.
    Nishiyama S; Uchino S; Sasabuchi Y; Masuyama T; Lefor AK; Sanui M
    PLoS One; 2024; 19(1):e0295952. PubMed ID: 38170714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Retrospective Study of the Efficacy and Safety of Naldemedine for Treatment of Opioid-Induced Constipation in Patients with Hepatobiliary Pancreatic Cancer.
    Kamiya T; Imai H; Fujita Y; Hiruta E; Masuno T; Yamazaki S; Tanaka H; Sandoh M; Takei S; Arai K; Nishiba H; Mogi J; Koizuka S; Saito T; Obayashi K; Kaira K; Minato K
    Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984494
    [No Abstract]   [Full Text] [Related]  

  • 8. Real-World Patient Characteristics and Treatment Patterns of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Cancer: A Multicenter Retrospective Chart Review Study.
    Hiruta E; Fujita Y; Imai H; Masuno T; Yamazaki S; Tanaka H; Kamiya T; Ito M; Takei S; Matsuura M; Nishiba H; Mogi J; Kotake M; Koizuka S; Minato K
    Medicina (Kaunas); 2021 Nov; 57(11):. PubMed ID: 34833451
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy of naldemedine for the treatment of opioid-induced constipation: A meta-analysis.
    Esmadi M; Ahmad D; Hewlett A
    J Gastrointestin Liver Dis; 2019 Mar; 28(1):41-46. PubMed ID: 30851171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective study of the efficacy and safety of naldemedine for opioid-induced constipation in thoracic cancer patients.
    Imai H; Fujita Y; Hiruta E; Masuno T; Yamazaki S; Tanaka H; Kamiya T; Sandoh M; Takei S; Arai K; Nishiba H; Mogi J; Kaira K; Minato K
    Thorac Cancer; 2022 Aug; 13(16):2301-2308. PubMed ID: 35790500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety and effectiveness of naldemedine for opioid-induced constipation in patients with advanced cancer in real-world palliative care settings: a multicenter prospective observational study.
    Shimizu M; Maeda I; Kessoku T; Ishiki H; Matsuura T; Hiratsuka Y; Matsuda Y; Hasegawa T; Imai K; Oyamada S; Satomi E;
    Support Care Cancer; 2024 Jul; 32(8):504. PubMed ID: 38985364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of naldemedine for opioid-induced constipation in older patients with cancer: a retrospective study.
    Imai H; Fujita Y; Hiruta E; Masuno T; Yamazaki S; Tanaka H; Kamiya T; Sandoh M; Takei S; Arai K; Nishiba H; Mogi J; Koizuka S; Saito T; Obayashi K; Kaira K; Minato K
    Eur J Gastroenterol Hepatol; 2024 May; 36(5):571-577. PubMed ID: 38477855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Naldemedine for Opioid-Induced Constipation in Children.
    Miura R; Utano T; Miura Y; Chiba K; Hasegawa A; Takafuji Y; Takahashi H; Tanzawa A; Iwahashi K; Yamatani A; Yotani N
    J Palliat Med; 2024 Oct; 27(10):1354-1358. PubMed ID: 39122251
    [No Abstract]   [Full Text] [Related]  

  • 14. Prevention and management of diarrhea associated with naldemedine among patients receiving opioids: a retrospective cohort study.
    Takagi Y; Osawa G; Kato Y; Ikezawa E; Kobayashi C; Aruga E
    BMC Gastroenterol; 2020 Jan; 20(1):25. PubMed ID: 32005157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer.
    Katakami N; Oda K; Tauchi K; Nakata K; Shinozaki K; Yokota T; Suzuki Y; Narabayashi M; Boku N
    J Clin Oncol; 2017 Jun; 35(17):1921-1928. PubMed ID: 28445097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripherally-active mu-opioid receptor antagonists for constipation in critically ill patients receiving opioids: A case-series and a systematic review and meta-analysis of the literature.
    Umbrello M; Venco R; Palandri C; Racagni M; Muttini S
    Neurogastroenterol Motil; 2023 Dec; 35(12):e14694. PubMed ID: 37869768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of naldemedine treatment for opioid-induced constipation in gastrointestinal cancer: a retrospective analysis.
    Nishiba H; Imai H; Fujita Y; Hiruta E; Masuno T; Yamazaki S; Tanaka H; Kamiya T; Ito M; Takei S; Matsuura M; Mogi J; Obayashi K; Minato K
    Ann Palliat Med; 2023 Jul; 12(4):697-707. PubMed ID: 37081703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer.
    Katakami N; Harada T; Murata T; Shinozaki K; Tsutsumi M; Yokota T; Arai M; Tada Y; Narabayashi M; Boku N
    J Clin Oncol; 2017 Dec; 35(34):3859-3866. PubMed ID: 28968171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naldemedine for the treatment of opioid-induced constipation in adults with chronic noncancer pain.
    Liu JJ; Quinton SE; Brenner DM
    Pain Manag; 2020 Sep; 10(5):301-306. PubMed ID: 32552565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-marketing surveillance of the safety and effectiveness of naldemedine in the management of opioid-induced constipation in patients with cancer pain in Japan.
    Takata K; Nakazawa M; Honda K; Hashimoto S
    Support Care Cancer; 2022 May; 30(5):3943-3954. PubMed ID: 35044484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.